Prosecution Insights
Last updated: April 19, 2026
Application No. 18/006,385

METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE AND ALLERGIC DISORDERS

Non-Final OA §112
Filed
Jan 21, 2023
Examiner
GANGLE, BRIAN J
Art Unit
1645
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Board Of Trustees Of The Leland Stanford Junior University
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
2y 8m
To Grant
92%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
718 granted / 940 resolved
+16.4% vs TC avg
Strong +15% interview lift
Without
With
+15.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
28 currently pending
Career history
968
Total Applications
across all art units

Statute-Specific Performance

§101
4.5%
-35.5% vs TC avg
§103
15.0%
-25.0% vs TC avg
§102
23.0%
-17.0% vs TC avg
§112
36.6%
-3.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 940 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicant’s amendment and remarks filed on 11/13/2025 are acknowledged. Claim 96 is amended. Claims 1-3, 6, 10-12, 43, 57, 202-203, 210, and 222 are cancelled. New claims 267-279 are added. Claims 85, 91, 95-96, 104-105, 126, and 267-279 are pending. Election/Restrictions Applicant’s election without traverse of Group II and microbiome-modulating therapy in the reply filed on 11/13/2025 is acknowledged. Claims 85, 91, 95-96, 104-105, 126, and 267-279 are currently under examination. Information Disclosure Statement The information disclosure statements filed on 4/10/2023, 2/12/2024, 6/5/2024, 8/16/2024, 8/6/2025, 8/25/2025, and 9/23/2025 have been considered. Signed copies are enclosed. Claim Objections Claims 85, 105, 267, 272, and 274 are objected to because of the following informalities: the claims contain the acronyms OTU and CFU. While acronyms are permissible shorthand in the claims, the first recitation of the term should include the full recitation followed by the acronym in parentheses. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), first paragraph: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 85, 91, 95-96, 104-105, 126, and 267-279 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for pre-AIA the inventor(s), at the time the application was filed, had possession of the claimed invention. The instant claims are drawn to methods of treating food allergy in subjects by administering a therapy wherein the subject was determined to have a decreased OTU abundance score relative to a control sample wherein the OTU abundance score was calculated using at least 20 of the OTUs of Table 1. The specification lists 64 OTUs in Table 1. Each includes a number or filename and some taxonomical information. For many of the OTUs, no genus or species names are provided and information is only provided to the family level. These OTUs do not correspond to information found in the art and no further information about these units is provided in the specification. Therefore, there is no description in the specification of what constitutes a member of a given OTU or how do determine such information. There is no description provided on how to practice the method without this information. Therefore, the claims do not meet the written description requirements of 35 USC 112a. The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 85, 91, 95-96, 104-105, 126, and 267-279 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claims 85 and 267 are indefinite because they refer to a Table in the specification. Where possible, claims are to be complete in themselves. Incorporation by reference to a specific figure or table "is permitted only in exceptional circumstances where there is no practical way to define the invention in words and where it is more concise to incorporate by reference than duplicating a drawing or table into the claim. Incorporation by reference is a necessity doctrine, not for applicant's convenience." Ex parte Fressola, 27 USPQ2d 1608, 1609 (Bd. Pat. App. & Inter. 1993) (citations omitted). Furthermore, the information provided in Table 1 does not actually provide enough information to determine what species or strains are part of a given OTU. Claim 267 is indefinite because it is dependent on a cancelled claim. Claim 269 is indefinite because it is not clear how one could treat an allergy that the subject does not have. Claims 275 and 276 are indefinite because it is not clear what measure is used to determine the percentage of bacteria. For example, the percentage could be determined based on weight, number of cells, number of species, and it is not clear which of these (or any other) measure is to be used. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 268 is rejected under 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The claim requires the subject to have a food allergy. However, the parent claim is drawn to a method of treating a food allergy in the subject. Therefore, in the parent claim, the subject must have a food allergy and the dependent claim does not further limit the parent. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian J Gangle whose telephone number is (571)272-1181. The examiner can normally be reached M-F, 9-6:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached at 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN GANGLE/Primary Examiner, Art Unit 1645
Read full office action

Prosecution Timeline

Jan 21, 2023
Application Filed
Jan 21, 2023
Response after Non-Final Action
Aug 09, 2023
Response after Non-Final Action
Jan 08, 2026
Non-Final Rejection — §112
Apr 09, 2026
Interview Requested
Apr 15, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12596121
COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECAL MICROBIOTA TRANSPLANT
2y 5m to grant Granted Apr 07, 2026
Patent 12595311
CHIMERIC ANTIGEN RECEPTORS AND RELATED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
2y 5m to grant Granted Apr 07, 2026
Patent 12589163
SHEDDING BLOCKING AGENTS WITH INCREASED STABILITY
2y 5m to grant Granted Mar 31, 2026
Patent 12589123
COMPOSITIONS AND METHODS COMPRISING CLOSTRIDIUM BUTYRICUM FOR THE TREATMENT OF CANCER
2y 5m to grant Granted Mar 31, 2026
Patent 12584084
USE OF BY-PRODUCTS FROM THE ALCOHOLIC BEVERAGE MANUFACTURING INDUSTRY
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
92%
With Interview (+15.4%)
2y 8m
Median Time to Grant
Low
PTA Risk
Based on 940 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month